{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:38:41Z","timestamp":1792539521834,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-14091-y","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:05:02Z","timestamp":1784883902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Y93H resistance-associated substitution in treatment-na\u00efve hepatitis C virus genotype 1b patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Dilip Kumar","family":"Kakru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Arcot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorabh","family":"Lakhanpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma Narsing","family":"Katkuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrin Reneus","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay M.","family":"Gaidhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakasini","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"6","key":"14091_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/microorganisms12061035","volume":"12","author":"M Sallam","year":"2024","unstructured":"Sallam M, Khalil R. Contemporary insights into hepatitis c virus: a comprehensive review. Microorganisms. 2024;12(6):1035.","journal-title":"Microorganisms"},{"issue":"7","key":"14091_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2174\/1389557517666170913111930","volume":"18","author":"D Das","year":"2018","unstructured":"Das D, Pandya M. Recent advancement of direct-acting antiviral agents (DAAs) in hepatitis C therapy. Mini Rev Med Chem. 2018;18(7):584\u201396.","journal-title":"Mini Rev Med Chem"},{"issue":"12","key":"14091_CR3","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3390\/cancers13123025","volume":"13","author":"S Brozzetti","year":"2021","unstructured":"Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D\u2019Alterio C, et al. HCC in the era of direct-acting antiviral agents (DAAs): surgical and other curative or palliative strategies in the elderly. Cancers. 2021;13(12):3025.","journal-title":"Cancers"},{"issue":"1","key":"14091_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/v14010016","volume":"14","author":"S Popping","year":"2021","unstructured":"Popping S, Cento V, Seguin-Devaux C, Boucher CA, de Salazar A, Heger E, et al. The European prevalence of resistance associated substitutions among direct acting antiviral failures. Viruses. 2021;14(1):16.","journal-title":"Viruses"},{"issue":"1","key":"14091_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s43066-022-00232-w","volume":"12","author":"F Butt","year":"2022","unstructured":"Butt F, Shahid M, Hassan M, Tawakkal F, Amin I, Afzal S, et al. A review on hepatitis C virus: role of viral and host-cellular factors in replication and existing therapeutic strategies. Egypt Liver J. 2022;12(1):71.","journal-title":"Egypt Liver J"},{"issue":"2","key":"14091_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","volume":"59","author":"J-M Pawlotsky","year":"2013","unstructured":"Pawlotsky J-M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. 2013;59(2):375\u201382.","journal-title":"J Hepatol"},{"key":"14091_CR7","volume-title":"Naturally occurring HCV NS5A\/B inhibitor resistance-associated mutations to direct-acting antivirals","author":"IHCOR Network","year":"2016","unstructured":"Network IHCOR, Nguyen LT, Hall N, Sheerin D, Carr M, De Gascun CF. Naturally occurring HCV NS5A\/B inhibitor resistance-associated mutations to direct-acting antivirals. London, England: SAGE Publications Sage UK; 2016."},{"key":"14091_CR8","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1590\/s1678-9946202264061","volume":"64","author":"APT Santos","year":"2022","unstructured":"Santos APT, Silva VCM, Mendes-Corr\u00eaa MC, Lemos MF, Malta FM, Santana RAF, et al. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A\/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis. Rev Inst Med Trop Sao Paulo. 2022;64:e61.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"8","key":"14091_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/00365521.2019.1652846","volume":"54","author":"M Kjellin","year":"2019","unstructured":"Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg A-S, Danielsson A, et al. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol. 2019;54(8):1042\u201350.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"14091_CR10","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","volume":"74","author":"C Sarrazin","year":"2021","unstructured":"Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. J Hepatol. 2021;74(6):1472\u201382.","journal-title":"J Hepatol"},{"issue":"1","key":"14091_CR11","first-page":"15","volume":"18","author":"JL Calleja","year":"2016","unstructured":"Calleja JL, Llerena S, Perell\u00f3 C, Crespo J. NS5A resistance: clinical implications and treatment possibilities. AIDS Rev. 2016;18(1):15\u201322.","journal-title":"AIDS Rev"},{"issue":"6","key":"14091_CR12","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/cid\/ciae431","volume":"79","author":"S Inzaule","year":"2024","unstructured":"Inzaule S, Easterbrook P, Latona A, Ford NP, Irving W, Matthews PC, et al. Prevalence of drug resistance associated substitutions in persons with chronic hepatitis C infection and virological failure following initial or re-treatment with pan-genotypic direct-acting antivirals: a systematic review and meta-analysis. Clin Infect Dis. 2024;79(6):1437\u201346.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"14091_CR13","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/ani14111578","volume":"14","author":"K Domrazek","year":"2024","unstructured":"Domrazek K, Jurka P. Application of next-generation sequencing (NGS) techniques for selected companion animals. Animals. 2024;14(11):1578.","journal-title":"Animals"},{"issue":"1","key":"14091_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12879-017-2817-7","volume":"17","author":"F Malta","year":"2017","unstructured":"Malta F, Gaspareto KV, Lisboa-Neto G, Carrilho FJ, Mendes-Correa MC, Pinho JRR. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect Dis. 2017;17(1):716.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"14091_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3851\/IMP3177","volume":"23","author":"F McPhee","year":"2018","unstructured":"McPhee F, Hernandez D, Zhou N, Ueland J, Yu F, Vellucci V, et al. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir. Antivir Ther. 2018;23(1):53\u201366.","journal-title":"Antivir Ther"},{"key":"14091_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"14091_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"14091_CR18","unstructured":"Eldridge S, Campbell M, Campbell M, Dahota A, Giraudeau B, Higgins J, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. Cochrane Methods Cochrane Database Syst Rev. 2016;10(suppl 1)."},{"issue":"1","key":"14091_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12877-025-05722-1","volume":"25","author":"D Lingamaiah","year":"2025","unstructured":"Lingamaiah D, Bushi G, Gaidhane S, Balaraman AK, Padmapriya G, Kaur I, et al. Falls among geriatric cancer patients: a systematic review and meta-analysis of prevalence and risk across cancer types. BMC Geriatr. 2025;25(1):179.","journal-title":"BMC Geriatr"},{"issue":"2","key":"14091_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I\u00b2 index? Psychol Methods. 2006;11(2):193.","journal-title":"Psychol Methods"},{"issue":"4","key":"14091_CR21","first-page":"195","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SA. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16(4):195\u2013203.","journal-title":"JBI Evid Implement"},{"issue":"7","key":"14091_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12325-015-0221-5","volume":"32","author":"F McPhee","year":"2015","unstructured":"McPhee F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv therapy. 2015;32(7):637\u201349.","journal-title":"Adv therapy"},{"key":"14091_CR23","doi-asserted-by":"crossref","unstructured":"Li Z, Chen Z-w, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-na\u00efve hepatitis C genotype 1b-infected patients in western China. Infect drug Resist. 2017:377\u201392.","DOI":"10.2147\/IDR.S146595"},{"issue":"4","key":"14091_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/infdis\/jiz154","volume":"220","author":"C-F Huang","year":"2019","unstructured":"Huang C-F, Hung C-H, Cheng P-N, Bair M-J, Huang Y-H, Kao J-H, et al. An open-label, randomized, active-controlled trial of 8 versus 12 weeks of elbasvir\/grazoprevir for treatment-naive patients with chronic hepatitis C genotype 1b infection and mild fibrosis (EGALITE Study): impact of baseline viral loads and NS5A resistance-associated substitutions. J Infect Dis. 2019;220(4):557\u201366.","journal-title":"J Infect Dis"},{"issue":"9","key":"14091_CR25","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1128\/AAC.00998-15","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59(9):5445\u201354.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"14091_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/jgh.12831","volume":"30","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, et al. Incidence of natural resistance mutations in na\u00efve chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30(2):252\u201361.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"14091_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12879-018-3125-6","volume":"18","author":"S Lanini","year":"2018","unstructured":"Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, et al. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis. 2018;18(1):223.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"14091_CR28","doi-asserted-by":"publisher","first-page":"20310","DOI":"10.1038\/srep20310","volume":"6","author":"Z-w Chen","year":"2016","unstructured":"Chen Z-w, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6(1):20310.","journal-title":"Sci Rep"},{"issue":"3","key":"14091_CR29","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1128\/JVI.02294-12","volume":"87","author":"DJ Bartels","year":"2013","unstructured":"Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87(3):1544\u201353.","journal-title":"J Virol"},{"key":"14091_CR30","doi-asserted-by":"crossref","unstructured":"Wu R, Geng D, Chi X, Wang X, Gao X, Xu H et al. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect Drug Resist. 2019:2987\u20133015.","DOI":"10.2147\/IDR.S218584"},{"issue":"5","key":"14091_CR31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","volume":"66","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem S, Mizokami M, Pianko S, Mangia A, Han K-H, Martin R, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910\u20138.","journal-title":"J Hepatol"},{"issue":"3","key":"14091_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/apt.13882","volume":"45","author":"E Elbasha","year":"2017","unstructured":"Elbasha E, Robertson M, Nwankwo C. The cost-effectiveness of testing for NS 5a resistance\u2010associated polymorphisms at baseline in genotype 1a\u2010infected (treatment\u2010na\u00efve and treatment\u2010experienced) subjects treated with all\u2010oral elbasvir\/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2017;45(3):455\u201367.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"14091_CR33","doi-asserted-by":"publisher","first-page":"304948262413008","DOI":"10.1177\/30494826241300881","volume":"1","author":"L Tastet","year":"2024","unstructured":"Tastet L, Salaun E, de Heer F, Kluin J, El-Hamamsy I, Chauvette V, et al. Mid-term clinical and hemodynamic outcomes in patients treated for aortic regurgitation and\/or ascending aorta aneurysm: the 3-year flight of the AVIATOR registry. J Heart Valve Soc. 2024;1(1):30494826241300881.","journal-title":"J Heart Valve Soc"},{"issue":"6","key":"14091_CR34","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.ahj.2015.08.023","volume":"170","author":"J Chandrasekhar","year":"2015","unstructured":"Chandrasekhar J, Mastoris I, Baber U, Sartori S, Schoos M, Bansilal S, et al. Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI\u2014rationale and study design of the prospective observational multicenter AVIATOR 2 registry. Am Heart J. 2015;170(6):1234\u201342.","journal-title":"Am Heart J"},{"issue":"8","key":"14091_CR35","doi-asserted-by":"publisher","first-page":"e656","DOI":"10.4244\/EIJ-D-21-01044","volume":"18","author":"J Chandrasekhar","year":"2022","unstructured":"Chandrasekhar J, Baber U, Sartori S, Goel R, Nicolas J, Vogel B, et al. Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. EuroIntervention. 2022;18(8):e656.","journal-title":"EuroIntervention"},{"key":"14091_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fmicb.2019.00535","volume":"10","author":"J Lu","year":"2019","unstructured":"Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, et al. Subtype-specific prevalence of hepatitis C virus NS5A resistance associated substitutions in Mainland China. Front Microbiol. 2019;10:535.","journal-title":"Front Microbiol"},{"issue":"6","key":"14091_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1089\/mdr.2018.0360","volume":"25","author":"W Huang","year":"2019","unstructured":"Huang W, Wang M, Gong Q, Yu D, Chen P, Lin J, et al. Comparison of naturally occurring resistance-associated substitutions between 2008 and 2016 in Chinese patients with chronic hepatitis C virus infection. Microb Drug Resist. 2019;25(6):944\u201350.","journal-title":"Microb Drug Resist"},{"issue":"1","key":"14091_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1469-0691.12056","volume":"19","author":"MR Capobianchi","year":"2013","unstructured":"Capobianchi MR, Giombini E, Rozera G. Next-generation sequencing technology in clinical virology. Clin Microbiol Infect. 2013;19(1):15\u201322.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"14091_CR39","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s00535-017-1328-z","volume":"52","author":"G Suda","year":"2017","unstructured":"Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, et al. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52(10):1122\u20139.","journal-title":"J Gastroenterol"},{"issue":"3","key":"14091_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3851\/IMP3181","volume":"23","author":"D Wyles","year":"2018","unstructured":"Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, et al. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2018;23(3):229\u201338.","journal-title":"Antivir Ther"},{"issue":"11","key":"14091_CR41","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1093\/jac\/dkaa304","volume":"75","author":"A de Salazar","year":"2020","unstructured":"de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, M\u00fcllhaupt B, et al. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir\/pibrentasvir regimen. J Antimicrob Chemother. 2020;75(11):3349\u201358.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"14091_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/apt.15633","volume":"51","author":"AD Singh","year":"2020","unstructured":"Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, et al. Systematic review with meta-analysis: impact of baseline resistance\u2010associated substitutions on the efficacy of glecaprevir\/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther. 2020;51(5):490\u2013504.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"14091_CR43","doi-asserted-by":"publisher","first-page":"8988","DOI":"10.1038\/s41598-018-26862-y","volume":"8","author":"A Bertoli","year":"2018","unstructured":"Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, et al. Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1\u20134 in Italy. Sci Rep. 2018;8(1):8988.","journal-title":"Sci Rep"},{"issue":"4","key":"14091_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54(4):352\u20134.","journal-title":"J Clin Virol"},{"issue":"19","key":"14091_CR45","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.4103\/0366-6999.166038","volume":"128","author":"Y Wang","year":"2015","unstructured":"Wang Y, Rao H-Y, Xie X-W, Wei L. Direct-acting antiviral agents resistance-associated polymorphisms in Chinese treatment-naive patients infected with genotype 1b hepatitis C virus. Chin Med J. 2015;128(19):2625\u201331.","journal-title":"Chin Med J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14091-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14091-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14091-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:48:02Z","timestamp":1792536482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14091-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14091"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14091-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable, as there were no human participants involved in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study does not involve any individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1847"}}